Ligand Pharmaceuticals (LGND) Non Operating Income (2010 - 2026)

Ligand Pharmaceuticals has disclosed Non Operating Income across 17 years of filings, most recently posting -$41.6 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at -$41.6 million, down 198.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.2 million (up 54.2% YoY), and the FY2025 annual result was -$89000.0, up 99.56% from the prior year.
• Non Operating Income came in at -$41.6 million for Q1 2026 at Ligand Pharmaceuticals, up from -$75.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $86.2 million in Q3 2025 to a low of -$75.1 million in Q4 2025.
• The 5-year median for Non Operating Income is -$4.3 million (2023), against an average of -$3.0 million.
• Across the five-year window, Non Operating Income plunged 33176.92% in 2023 and soared 1010.69% in 2025, its largest moves.
• Ligand Pharmaceuticals' Non Operating Income stood at $44.2 million in 2022, then sank by 174.52% to -$33.0 million in 2023, then jumped by 79.64% to -$6.7 million in 2024, then tumbled by 1019.04% to -$75.1 million in 2025, then jumped by 44.58% to -$41.6 million in 2026.
• The last three Non Operating Income figures came in at -$41.6 million (Q1 2026), -$75.1 million (Q4 2025), and $86.2 million (Q3 2025), per Business Quant data.